An addictive nicotinic acetylcholine receptor agonist. Delivery route changes exposure; tobacco-smoke harms and nicotine pharmacology need separate treatment.
Nicotine activates receptors normally used by acetylcholine and participates in reinforcement and dependence. Medicines containing nicotine are used in smoking cessation. Neither that use nor short-term changes in attention establish a case for starting nicotine as a cognitive enhancer.
This entry covers receptor pharmacology and dependence, rather than establishing a use for cognitive enhancement.
Assessment belongs to each claim and outcome. An article’s editorial status is not a grade of a substance’s safety or efficacy.Receptor activation changes neurotransmitter release, including dopamine signaling involved in reinforcement. [2]
Descriptions of experience in their reported context. Direction does not imply benefit, and these observations do not define a universal intensity score.
Dependence can produce cravings during abstinence; relief after nicotine can reflect reversal of withdrawal. [2]
What the research measured, for whom, and under which exposure. Findings remain attached to the study’s task or clinical endpoint.
Not assessed. No sourced measured outcomes have been curated for this article.
Published exposure records, distinguished by source category. These describe study or reference context and are not personal dosing recommendations.
Not assessed. No sourced exposure records have been curated.
Absorption, metabolism and elimination depend on the analyte, route, formulation, physiology and other exposures.
Approximate plasma elimination after smoking or intravenous administration in the review. Slower terminal release from tissues is also described. [1]
The modeled analyte is Nicotine. The curve begins after absorption and distribution; it does not predict onset, felt effects, or an individual’s response.
Route: Inhalation or intravenous administration. Formulation: Cigarette smoke or intravenous nicotine in reviewed kinetic studies. Population: Adults represented in the pharmacology review.
Approximate plasma elimination after smoking or intravenous administration in the review. Slower terminal release from tissues is also described. Source & context
Approximate estimate: 2 hours.
The model uses this single reported estimate; no range is inferred.
Model: fraction remaining = 2−time / half-life. Assumes a single exposure, instantaneous distribution, and a constant half-life for Nicotine. Formation of metabolites, repeated exposure, and interactions are not modeled. Source & context
2 hoursApproximate estimate [1]
Approximate plasma elimination after smoking or intravenous administration in the review. Slower terminal release from tissues is also described.
Inhaled and medicinal products have different absorption profiles. Product contents cannot be equated with an absorbed dose. [1]
Related observationGenetics, medicines, pregnancy and kidney disease can affect nicotine disposition. [1]
Related observationAdverse effects, interactions, tolerance and withdrawal in the cited contexts. This section is not an exhaustive interaction checker.
Reward, tolerance and withdrawal belong in any assessment of perceived cognitive benefit. [2]
A nicotine molecule diagram does not describe the many toxic exposures from burning tobacco. Medicinal replacement and smoking are not interchangeable risk categories. [2]
The source, the finding and its limitations. Funding information is reported where curated; an unassessed disclosure does not mean a study had no commercial funding.
Describes route-dependent absorption, elimination and metabolic modifiers.
Limitations Population summaries differ by product and exposure history; a plasma half-life is not a duration-of-effect estimate.
Funding / disclosures Not assessed; consult the original disclosure.
Explains receptor signaling, reinforcement and the cycle of dependence and withdrawal.
Limitations Not a trial of nicotine enhancement in people who do not use tobacco.
Funding / disclosures Not assessed; consult the original disclosure.
Source for molecular identity, formula, molecular weight and the structure diagram.
Limitations A compound record does not establish a product's purity, identity or clinical benefit.
Funding / disclosures Public database maintained by NCBI.
Each relationship retains its participants, roles and context. Shared membership does not imply that substances should be combined.
Receptor pharmacology in a clinical review of dependence.
Limitation Dependence and withdrawal confound claims of enhancement.
Evidence strength: not formally assessed.
Route-dependent human nicotine pharmacokinetics.
Limitation CYP2A6 metabolism does not make nicotine a proxy for tobacco-smoke induction of CYP1A2.
Evidence strength: not formally assessed.
Not assessed. Absence of a legal record is not a statement of legal status.
This article is a sourced draft. Editorial review has not been recorded. Content date: Sep 29, 2026.